AAD VMX 2021: Long-Term Safety of Sofpironium Bromide Gel for Axillary Hyperhidrosis Demonstrated in 52-Week Study
A 15% gel formulation is currently undergoing evaluation for approval in the United States
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.